MITCHELL GLASER: Open Payments
NPI 1598789521 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$255,531 in 479 payments from 19 companies in 2025. Trend: 2023 $148,720 · 2024 $188,121 · 2025 $255,531
Speaker / faculty: $191,675Consulting: $31,217Travel & lodging: $22,059Food & beverage: $10,580
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 148 | $112,246 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 76 | $58,997 |
| Janssen Pharmaceuticals, Inc | 49 | $27,987 |
| Neurocrine BioSciences, Inc. | 35 | $20,147 |
| ABBVIE INC. | 47 | $19,405 |
| Teva Pharmaceuticals USA, Inc. | 22 | $14,805 |
| Alkermes, Inc. | 17 | $311 |
| Supernus Pharmaceuticals, Inc. | 22 | $291 |
| Lundbeck LLC | 12 | $285 |
| Axsome Therapeutics, Inc. | 21 | $276 |
Products named: COBENFY, CAPLYTA, SPRAVATO, INGREZZA, VRAYLAR, UZEDY, REXULTI, Qelbree.
Industry payments across IL — which companies pay providers there.
